If you forced a rheumatologist to rank every biologic for rheumatoid arthritis from most to least effective, the answer would depend entirely on which data you trust — and which patient is sitting across from them. Network meta-analyses place certolizumab pegol at the top when combined with DMARDs, followed by tocilizumab, anakinra, and rituximab, with adalimumab and etanercept trailing behind. But real-world data tells a different story: adalimumab, etanercept, and golimumab actually outperform infliximab in practice, and JAK inhibitors as a class have shown higher effectiveness than TNF inhibitors altogether. The uncomfortable truth is that roughly 40 percent of biological therapies fail because the targeting simply does not match the individual patient’s disease biology. This matters for readers of a brain health site more than you might expect.
Chronic systemic inflammation — the kind rheumatoid arthritis drives relentlessly — has been linked in multiple studies to accelerated cognitive decline and increased dementia risk. Getting RA under control is not just about joint pain. It is about tamping down a fire that can damage the brain over decades. This article walks through every FDA-approved biologic class, ranks them using the best available evidence, breaks down costs and safety signals including infection risks that are especially relevant for older adults, and covers the biosimilar market that is finally making these drugs more accessible. For anyone navigating RA treatment decisions — whether for themselves or for a family member who is also managing cognitive health concerns — understanding how these drugs stack up against each other is essential groundwork for an informed conversation with a rheumatologist.
Table of Contents
- How Do Rheumatologists Actually Rank Biologics for Rheumatoid Arthritis?
- Why the “Best” Biologic Fails 40 Percent of the Time
- Infection and Cardiovascular Risks That Matter Most for Aging Brains
- What Each Biologic Class Actually Does and When to Choose It
- The Cost Problem No One Wants to Talk About
- How Biosimilars Are Changing the Biologic Landscape
- What Precision Medicine May Mean for Biologic Selection
- Conclusion
- Frequently Asked Questions
How Do Rheumatologists Actually Rank Biologics for Rheumatoid Arthritis?
The ranking depends on the lens. A large network meta-analysis published in PLOS ONE compared biologics combined with conventional DMARDs and found certolizumab pegol at the top of the effectiveness hierarchy, followed by tocilizumab, anakinra, rituximab, then a cluster of golimumab, infliximab, and abatacept performing similarly, with adalimumab and etanercept rounding out the group. That ranking surprises many patients, since Humira (adalimumab) and Enbrel (etanercept) are by far the most prescribed biologics in the United States. Popularity does not equal superiority — it often reflects insurance formularies, marketing history, and physician familiarity. Real-world effectiveness data from Frontiers in Pharmacology complicates the picture further. In actual clinical practice, adalimumab, etanercept, and golimumab showed higher effectiveness than infliximab.
The gap between clinical trial rankings and real-world performance likely reflects differences in patient adherence, dosing flexibility, and the practical realities of infusion versus self-injection. An infusion center drug like Remicade requires regular hospital visits, which older adults or cognitively impaired patients may struggle to maintain consistently. Then there are jak inhibitors — technically targeted synthetic DMARDs rather than true biologics, but grouped alongside them in treatment guidelines. In real-world settings, JAK inhibitors showed higher effectiveness than TNF inhibitors and other biologics. Phase III trial data confirmed that baricitinib and upadacitinib were more efficacious than TNF inhibitors specifically, while tofacitinib and filgotinib performed comparably. The catch, as we will discuss, is that JAK inhibitors carry safety signals that have made regulators and many rheumatologists cautious.
Why the “Best” Biologic Fails 40 Percent of the Time
The statistic that should humble every ranking list: 40 percent of biological therapies fail due to inaccurate targeting. Rheumatoid arthritis is not one disease with one mechanism. Some patients are driven primarily by TNF-alpha, others by interleukin-6, others by B-cell dysfunction. Current clinical practice largely treats biologic selection as educated guessing — start with a TNF inhibitor because the evidence base is largest, and if it fails, switch to a different mechanism of action. Anti-TNF drugs illustrate this problem well.
Even when a TNF inhibitor works initially, some patients form antibodies against the drug itself, causing it to lose effectiveness over time. This immunogenicity problem is particularly common with infliximab and adalimumab, and it is one reason rheumatologists almost universally recommend taking methotrexate alongside a biologic — the methotrexate suppresses the immune response that would otherwise neutralize the biologic. However, if a patient cannot tolerate methotrexate due to liver concerns or side effects, etanercept becomes a more attractive option because it shows comparable efficacy as monotherapy without methotrexate. For older adults managing both RA and cognitive health, the trial-and-error approach to biologic selection carries a particular cost. Each failed biologic means months of continued systemic inflammation while waiting for the next drug to take effect. Emerging biomarker research may eventually allow rheumatologists to match patients to the right biologic on the first try, but that precision medicine future has not arrived yet.
Infection and Cardiovascular Risks That Matter Most for Aging Brains
The safety profile differences between biologic classes become especially important for patients over 65, who are simultaneously at higher risk for infections, cardiovascular events, and cognitive decline. JAK inhibitors carry a herpes zoster risk of 11.54 per 100 person-years, compared to 4.88 for TNF inhibitors — more than double. Herpes zoster reactivation is not just painful; in older adults, it can lead to postherpetic neuralgia that lasts months and significantly impairs quality of life and cognitive function through chronic pain and sleep disruption. Serious bacterial infection rates are more comparable between the two classes — 1.39 per 100 person-years for JAK inhibitors versus 1.32 for TNF inhibitors.
That near-equivalence is somewhat reassuring, but any serious infection in an older adult with compromised immunity can trigger delirium, hospitalization, and lasting cognitive setbacks. The cardiovascular picture is murkier. JAK inhibitors and biologics show similar rates of major adverse cardiovascular events overall, but the ORAL Surveillance study found increased MACE risk with tofacitinib specifically in patients who already had cardiovascular risk factors. Given that cardiovascular disease and dementia share many of the same risk factors, this finding deserves serious weight in treatment decisions for patients with overlapping risk profiles. The practical takeaway: if a patient is over 65 with cardiovascular risk factors and cognitive concerns, many rheumatologists will lean toward a TNF inhibitor or abatacept rather than a JAK inhibitor, even if the JAK inhibitor might be marginally more effective on paper.
What Each Biologic Class Actually Does and When to Choose It
The six FDA-approved biologic categories for RA each target a different piece of the inflammatory cascade. TNF inhibitors — adalimumab, etanercept, infliximab, certolizumab pegol, and golimumab — remain the most widely used class and are typically the first biologic tried. They block tumor necrosis factor, a protein that drives joint inflammation. IL-6 inhibitors like tocilizumab and sarilumab target interleukin-6 and tend to be especially effective at reducing systemic inflammation markers like CRP, which makes them worth considering when systemic inflammation and its downstream cognitive effects are a primary concern. Abatacept, a T-cell co-stimulation blocker, works differently from most biologics by preventing T-cell activation rather than neutralizing a single cytokine. It has a notably mild side-effect profile, making it attractive for patients who are infection-prone or frail.
Rituximab, a B-cell depleter, is typically reserved for patients who have failed TNF inhibitors and is given as an infusion every six months. Anakinra, the IL-1 blocker, is the least commonly used biologic for RA because it requires daily injections, though its position in meta-analysis rankings is surprisingly strong. Among JAK inhibitors, the tradeoff is clear: tofacitinib, baricitinib, and upadacitinib offer oral convenience and strong efficacy, but the safety signals — particularly herpes zoster and the cardiovascular concerns with tofacitinib — mean the 2021 ACR guidelines recommend trying a biologic before a JAK inhibitor in most cases. According to those ACR guidelines, methotrexate remains the recommended first-line treatment for moderate-to-high disease activity RA. Biologics and JAK inhibitors enter the picture when methotrexate alone is insufficient. This stepwise approach frustrates some patients who want to jump straight to a biologic, but the evidence supports starting with methotrexate and adding a biologic if needed.
The Cost Problem No One Wants to Talk About
Biologics generally cost between 25,000 and 40,000 dollars per year, but the cost per effectively treated patient — which accounts for the drugs that fail — tells a more honest story. Etanercept comes out ahead at approximately 43,935 dollars per effectively treated patient over one year, followed by golimumab at 49,589 dollars, adalimumab at 52,752 dollars, and abatacept at 62,300 dollars. Infliximab is the most expensive by this measure at 101,402 dollars per effectively treated patient, driven partly by infusion costs and partly by lower real-world persistence rates. These numbers matter enormously for patients on fixed incomes, which describes many older adults managing both RA and early cognitive decline. Sarilumab alone runs approximately 39,000 dollars per year at list price.
Insurance coverage, manufacturer copay assistance programs, and the growing biosimilar market can dramatically reduce out-of-pocket costs, but navigating these programs requires organizational capacity that cognitively impaired patients may not have without a caregiver’s help. A rheumatologist who ranks biologics without discussing cost is not giving a complete ranking. The financial burden also affects adherence. Patients who cannot afford their biologic skip doses or stretch intervals, which not only reduces effectiveness but increases the risk of developing anti-drug antibodies that can render the biologic permanently useless. For caregivers helping a loved one manage RA alongside dementia, ensuring consistent medication access is as important as choosing the right drug in the first place.
How Biosimilars Are Changing the Biologic Landscape
The biosimilar market is finally making a dent in biologic costs. FDA-approved biosimilars now exist for adalimumab, etanercept, infliximab, rituximab, and tocilizumab. In early 2025, the FDA approved Avtozma, a tocilizumab biosimilar, expanding options further. Infliximab biosimilars have achieved 48 percent market share as of the third quarter of 2024, while adalimumab biosimilars reached 23 percent market share by the end of 2024.
These are not generic drugs — they are biologically similar versions that have demonstrated equivalent safety and efficacy through rigorous testing. For patients and caregivers weighing biologic options, biosimilar availability should factor into the decision. If two biologics are roughly equivalent in effectiveness for a given patient, choosing the one with available biosimilars can provide significant cost savings and protect against supply disruptions. Ask the prescribing rheumatologist directly whether a biosimilar is available and appropriate.
What Precision Medicine May Mean for Biologic Selection
The 40 percent failure rate of current biologic therapies points to an obvious need: better tools for matching patients to drugs before starting treatment. Research into biomarkers that predict response to specific biologic mechanisms is active but has not yet produced clinically validated tests for routine use. Some promising work involves gene expression profiling and synovial tissue analysis to determine whether a patient’s RA is TNF-driven, IL-6-driven, or driven by another pathway entirely.
For the brain health community, this research carries double significance. More precise biologic selection would mean faster control of systemic inflammation, fewer months spent on ineffective drugs, and potentially reduced cumulative inflammatory burden on the brain. Until those tools arrive, the pragmatic approach remains: start with methotrexate, add a biologic if needed, monitor response carefully, and switch mechanisms rather than cycling through drugs in the same class if the first choice fails.
Conclusion
Ranking biologics for rheumatoid arthritis is not as simple as creating a top-ten list. Meta-analysis data favors certolizumab and tocilizumab, real-world data favors adalimumab and etanercept, and JAK inhibitors outperform both categories in some measures but carry safety concerns that make them a second-line choice for many patients. The 40 percent failure rate of biological therapies underscores that the best biologic is the one that works for the individual patient sitting in the exam room, not the one that topped an aggregate statistical analysis.
For older adults managing RA alongside cognitive health concerns, the treatment decision involves weighing effectiveness against infection risk, cardiovascular safety, cost, and the practical demands of each drug’s administration. Methotrexate remains the starting point per ACR guidelines, biosimilars are making biologics more affordable, and the future of precision medicine may eventually eliminate the costly trial-and-error process. In the meantime, the most productive step a patient can take is an honest conversation with their rheumatologist about which biologic makes sense given their complete medical picture — joints and brain included.
Frequently Asked Questions
Are biologics safe for elderly patients with rheumatoid arthritis?
Biologics are used in older adults, but infection risk increases with age and immunosuppression. Serious bacterial infection rates run approximately 1.3 to 1.4 per 100 person-years across biologic classes. Rheumatologists typically favor drugs with milder safety profiles, such as abatacept or etanercept, for frail or elderly patients and monitor more frequently.
Can rheumatoid arthritis inflammation contribute to dementia risk?
Chronic systemic inflammation is a recognized risk factor for cognitive decline and has been associated with increased dementia risk in epidemiological studies. Controlling RA-related inflammation with effective treatment, including biologics when necessary, may help reduce this cumulative burden on the brain.
What happens if my first biologic stops working?
Anti-TNF drugs in particular can lose effectiveness when patients develop antibodies against the drug. When a biologic fails, rheumatologists typically switch to a different mechanism of action rather than trying another drug in the same class. Taking methotrexate alongside a biologic reduces the likelihood of developing these anti-drug antibodies.
Are JAK inhibitors better than biologics for rheumatoid arthritis?
JAK inhibitors have shown higher effectiveness than TNF inhibitors in real-world data, and baricitinib and upadacitinib outperformed TNF inhibitors in phase III trials. However, JAK inhibitors carry higher herpes zoster risk — 11.54 versus 4.88 per 100 person-years — and the ORAL Surveillance study raised cardiovascular concerns with tofacitinib in at-risk patients. Most guidelines recommend trying a biologic before a JAK inhibitor.
How much do biologics for RA cost without insurance?
List prices generally range from 25,000 to 40,000 dollars per year, with sarilumab at approximately 39,000 dollars annually. When accounting for treatment failures, cost per effectively treated patient ranges from about 44,000 dollars for etanercept to over 101,000 dollars for infliximab. Biosimilars and manufacturer assistance programs can substantially reduce out-of-pocket costs.
